Supernus Pharmaceuticals, Inc.
SUPN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $661,817 | $607,521 | $667,238 | $579,775 |
| % Growth | 8.9% | -8.9% | 15.1% | – |
| Cost of Goods Sold | $77,906 | $83,779 | $87,221 | $75,061 |
| Gross Profit | $583,911 | $523,742 | $580,017 | $504,714 |
| % Margin | 88.2% | 86.2% | 86.9% | 87.1% |
| R&D Expenses | $108,796 | $91,593 | $74,552 | $90,467 |
| G&A Expenses | $247,282 | $236,661 | $109,433 | $105,050 |
| SG&A Expenses | $335,782 | $336,361 | $377,221 | $304,759 |
| Sales & Mktg Exp. | $88,500 | $99,700 | $267,788 | $199,709 |
| Other Operating Expenses | $57,667 | $101,057 | $82,120 | $23,459 |
| Operating Expenses | $502,245 | $529,011 | $533,893 | $418,685 |
| Operating Income | $81,666 | -$5,269 | $46,124 | $86,029 |
| % Margin | 12.3% | -0.9% | 6.9% | 14.8% |
| Other Income/Exp. Net | $16,204 | $8,038 | $14,619 | -$12,854 |
| Pre-Tax Income | $97,870 | $2,769 | $60,743 | $73,175 |
| Tax Expense | $24,005 | $1,453 | $32 | $19,751 |
| Net Income | $73,865 | $1,316 | $60,711 | $53,424 |
| % Margin | 11.2% | 0.2% | 9.1% | 9.2% |
| EPS | 1.34 | 0.024 | 1.13 | 1.01 |
| % Growth | 5,460.2% | -97.9% | 11.9% | – |
| EPS Diluted | 1.32 | 0.024 | 1.04 | 0.98 |
| Weighted Avg Shares Out | 55,100 | 54,536 | 53,665 | 53,099 |
| Weighted Avg Shares Out Dil | 55,959 | 55,507 | 61,680 | 54,357 |
| Supplemental Information | – | – | – | – |
| Interest Income | $16,204 | $10,453 | $21,689 | $10,569 |
| Interest Expense | $0 | $2,415 | $7,070 | $23,423 |
| Depreciation & Amortization | $80,414 | $84,859 | $85,543 | $32,595 |
| EBITDA | $178,284 | $90,043 | $153,356 | $129,193 |
| % Margin | 26.9% | 14.8% | 23% | 22.3% |